Synklino
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection.
Synklino has raised €30M across 2 funding rounds from 2 investors, most recently a Series A round in Jun 2022. Based in Lyngby, Denmark; founded 2017; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€30M
€29,800,000
Funding rounds
2
Investors
2
distinct backers
Active since
2020-10
latest 2022-06
Funding by year
EUR raised per yearSynklino — funding by year — interactive chart.
Data table
| Synklino — funding by year | |
|---|---|
| 2020 | €0 |
| 2022 | €30M |
Signals
Medium confidenceRaise-next likelihood9
base rate 44% for Series A
- ▼ Past typical raise window
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ 9y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-09 | Series A | €30M | — | View deal → |
| 2020-10-07 | Other | €0 | EIR Ventures,Vækstfonden | View deal → |
Investors
2Related news
- Synklino Closes EUR 29.8M Series A Fundingfinsmes.com · 2022-06
- finsmes.com
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Oura Health€779MFinland · Healthtech
Global coverage: FundingData